^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IKZF3 degrader

    Related drugs:
    3ms
    CFT7455-1101: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov)
    P1, N=224, Active, not recruiting, C4 Therapeutics, Inc. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Dec 2025 | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cemsidomide (CFT7455)
    9ms
    Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P1/2 trial
    12ms
    Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (clinicaltrials.gov)
    P1, N=7, Completed, Kymera Therapeutics, Inc. | Suspended --> Completed | N=80 --> 7
    Trial completion • Enrollment change
    |
    KT-413
    over1year
    CFT7455-1101: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=224, Recruiting, C4 Therapeutics, Inc. | N=158 --> 224
    Enrollment change
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cemsidomide (CFT7455)
    over1year
    NX-2127-001: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=266, Recruiting, Nurix Therapeutics, Inc. | Active, not recruiting --> Recruiting | N=160 --> 266 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD4 (CD4 Molecule)
    |
    zelebrudomide (NX-2127)
    over1year
    Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. (PubMed, J Med Chem)
    KT-413 achieves concurrent degradation of these proteins by functioning as both a heterobifunctional degrader and a molecular glue. Based on the demonstrated activity and safety of KT-413 in preclinical studies, a phase 1 clinical trial in B-cell lymphomas, including MYD88 mutant ABC DLBCL, is currently underway.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IKZF1 (IKAROS Family Zinc Finger 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    KT-413
    over1year
    Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=158, Recruiting, C4 Therapeutics, Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cemsidomide (CFT7455)
    almost2years
    Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. (PubMed, Science)
    Treatment of chronic lymphocytic leukemia with NX-2127 achieves >80% degradation of BTK in patients and demonstrates proof-of-concept therapeutic benefit. These data reveal an oncogenic scaffold function of mutant BTK that confers resistance across clinically approved BTK inhibitors but is overcome by BTK degradation in patients.
    Journal
    |
    BTK (Bruton Tyrosine Kinase) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    BTK mutation
    |
    zelebrudomide (NX-2127)
    almost2years
    Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. (PubMed, J Med Chem)
    NX-2127 is orally bioavailable, exhibits in vivo degradation across species, and demonstrates efficacy in preclinical oncology models. NX-2127 has advanced into first-in-human clinical trials and achieves deep and sustained degradation of BTK following daily oral dosing at 100 mg.
    Preclinical • Journal • Immunomodulating
    |
    BTK (Bruton Tyrosine Kinase) • IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    zelebrudomide (NX-2127)
    almost2years
    Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL (clinicaltrials.gov)
    P1, N=80, Suspended, Kymera Therapeutics, Inc.
    Trial completion date • Trial primary completion date
    |
    KT-413
    2years
    Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Salarius Pharmaceuticals, LLC | Trial completion date: Aug 2026 --> Aug 2027 | Initiation date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    deuterated S-avadomide (SP-3164)
    2years
    Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL (clinicaltrials.gov)
    P1, N=80, Suspended, Kymera Therapeutics, Inc. | Recruiting --> Suspended
    Trial suspension
    |
    KT-413